- Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates(2019)
Authors: Bram Verstockt, Erwin Dreesen, An Outtier, Nathalie Van den Berghe, Isolde Aerden, Gert Van Assche, Ann Gils, Séverine Vermeire, Marc Ferrante
Pages: 864 - 872
- USTEKINUMAB INDUCES LIMITED MUCOSAL HEALING AFTER 6 MONTHS IN A REAL-LIFE, PROSPECTIVE COHORT OF PATIENTS WITH REFRACTORY CROHN'S DISEASE(2018)
Authors: Bram Verstockt, Maja Noman, Isolde Aerden, Miet Peeters, Els Brouwers, Vera Ballet, Liesbeth Vandersmissen, Gert A Van Assche, Ann Gils, Séverine Vermeire, et al.
Pages: S836 - S836
- Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease(2013)
Authors: Gert Van Assche, Dirk Vanbeckevoort, Paul Rutgeerts, Séverine Vermeire, Isolde Aerden
Pages: 950 - 957
- Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease(2012)
Authors: Marc Ferrante, Séverine Vermeire, Isolde Aerden, Gert Van Assche, Paul Rutgeerts
Pages: 2218 - 2224
- Effects of Infliximab Therapy on Transmural Lesions Assessed by MRI Enteroclysis in Patients With Heal Crohn's Disease: The ACTIF Study(2011)
Authors: Gert Van Assche, Karin A Hermann, Edouard Louis, Simon Everett, Jean-Frederic Colombel, Jean Francois Rahier, Damian J Talon, Dirk Vanbeckevoort, Paul Meunier, Olivier Ernst, et al.
Pages: S73 - S73
- Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: A controlled randomized trial(2008)
Authors: Séverine Vermeire, Gert Van Assche, Isolde Aerden, Paul Rutgeerts
Pages: 1123 - 1129